1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
Adenosine Receptor A3 (ADORA3) pipeline Target constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report Adenosine Receptor A3 - Pipeline Review, H2 2020, outlays comprehensive information on the Adenosine Receptor A3 (ADORA3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Adenosine Receptor A3 (ADORA3) - The adenosine A3 receptor, also known as ADORA3, is an adenosine receptor. Adenosine A3 receptors are G protein-coupled receptors that mediates a sustained cardioprotective function during cardiac ischemia. It is involved in the inhibition of neutrophil degranulation in neutrophil mediated tissue injury, it mediate both cell proliferation and cell death. A3 adenosine receptor (A3AR) is the only adenosine subtype to be over expressed in inflammatory and cancer cells, thus making it a potential target for therapy. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 1, 6, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Report covers products from therapy areas Immunology, Gastrointestinal, Metabolic Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Male Health, Oncology, Ophthalmology, Infectious Disease, Musculoskeletal Disorders, Respiratory and Women's Health which include indications Non-Alcoholic Steatohepatitis (NASH), Diabetic Nephropathy, Glaucoma, Inflammation, Kidney Fibrosis, Rheumatoid Arthritis, Arthritis, Autoimmune Disorders, Chemotherapy Induced Pain, Chronic Inflammation, Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Coronavirus Disease 2019 (COVID-19), Erectile Dysfunction, Female Sexual Dysfunction, Hepatocellular Carcinoma, Inflammatory Pain, Liver Cancer, Male Sexual Dysfunction, Melanoma, Neurodegenerative Diseases, Neuropathic Pain (Neuralgia), Non Alcoholic Fatty Liver Disease (NAFLD), Obesity, Plaque Psoriasis (Psoriasis Vulgaris), Prostate Cancer, Psoriasis and Ulcerative Colitis.
Furthermore, this report also reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Adenosine Receptor A3 (ADORA3)
- The report reviews Adenosine Receptor A3 (ADORA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Adenosine Receptor A3 (ADORA3) targeted therapeutics and enlists all their major and minor projects
- The report assesses Adenosine Receptor A3 (ADORA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Adenosine Receptor A3 (ADORA3) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Adenosine Receptor A3 (ADORA3)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Adenosine Receptor A3 (ADORA3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Introduction
Adenosine Receptor A3 (ADORA3) - Therapeutics Development
Adenosine Receptor A3 (ADORA3) - Therapeutics Assessment
Adenosine Receptor A3 (ADORA3) - Companies Involved in Therapeutics Development
BIO-205 - Drug Profile
CF-602 - Drug Profile
Drug to Agonize ADORA3 for Chemotherapy Induced Pain - Drug Profile
FM-1203 - Drug Profile
FM-1302 - Drug Profile
LJ-1888 - Drug Profile
LJ-2698 - Drug Profile
namodenoson - Drug Profile
PBF-1650 - Drug Profile
PBF-677 - Drug Profile
piclidenoson - Drug Profile
Small Molecule to Antagonize ADORA3 for Chronic Obstructive Pulmonary Disease - Drug Profile
Small Molecules for Autoimmune Disorders, Inflammation, Liver Cancer and Metabolic Disorders - Drug Profile
Small Molecules to Agonize ADORA3 for Chronic Inflammation and Neurodegenerative Diseases - Drug Profile
Small Molecules to Antagonize ADORA3 for Kidney Fibrosis - Drug Profile
Small Molecules to Target A3AR for Sexual Dysfunction - Drug Profile
Adenosine Receptor A3 (ADORA3) - Product Development Milestones
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BioIntervene Inc
- Can-Fite BioPharma Ltd
- Future Medicine Co Ltd
- Palo BioFarma SL